Related Experiment Videos
Chemotherapy in metastatic non-small-cell lung cancer
1Thoracic Oncology, Vanderbilt University, Nashville, Tennessee, USA.
Abstract:
Over the last decade, a group of new agents with differing mechanisms of action have shown great promise in early clinical studies in non-small-cell lung cancer (NSCLC). These include the taxanes docetaxel (Taxotere) and paclitaxel (Taxol); the nucleoside analog gemcitabine (Gemzar); the vinca alkaloid vinorelbine (Navelbine); the topoisomerase-I inhibitor irinotecan (Camptosar, CPT-11); and the bioreductive agent tirapazamine. Cisplatin (Platinol), which has been the "backbone" of combination chemotherapy in patients with NSCLC because of its proven single-agent activity, has been examined in combination with these agents as well as radiation and surgery in numerous trials. This article summarizes trials of these combination therapies in the treatment of NSCLC.
Insights
New chemotherapy agents show promise for non-small-cell lung cancer (NSCLC). This review summarizes combination therapy trials using agents like taxanes, gemcitabine, and cisplatin in NSCLC treatment.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Non-small-cell lung cancer (NSCLC) treatment has evolved with novel therapeutic agents.
- Cisplatin has been a standard chemotherapy backbone for NSCLC.
- Emerging drugs demonstrate potential in early clinical studies.
Purpose of the Study:
- To review clinical trials of combination therapies for NSCLC.
- To summarize the efficacy of novel agents in NSCLC treatment.
Main Methods:
- Literature review of clinical trials involving NSCLC.
- Analysis of combination chemotherapy regimens.
- Inclusion of agents such as taxanes, gemcitabine, vinorelbine, irinotecan, and tirapazamine.
Main Results:
- Several new agents show promise in early-phase NSCLC trials.
- Cisplatin-based combinations are extensively studied.
- Combination therapies are being investigated with radiation and surgery.
Conclusions:
- Novel agents offer new therapeutic avenues for NSCLC.
- Combination strategies are crucial for advancing NSCLC treatment.
- Further research is needed to establish optimal treatment protocols.